PFAS Testing Market worth $0.95 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global PFAS testing market will grow from $0.50 billion in 2026 to $0.95 billion by 2031, a 13.7% CAGR, driven by tighter environmental regulations and demand for ultra-trace contaminant detection. LC-MS/MS is forecast to grow at a 15.0% CAGR and instruments at 14.5%, with water testing the largest application segment. Consolidation is expanding laboratory capacity, including SGS's acquisitions of K Prime in July 2026 and RTI Laboratories in January 2025.

Analysis

The addressable spend is too small to move consolidated earnings at TMO, DHR, or A, but it can create a higher-quality replacement cycle within their environmental-analysis franchises: regulated workflows attach recurring columns, standards, sample-prep and service revenue after an initial instrument sale. WAT has the most direct product-fit torque because LC separations and PFAS-certified consumables are integral to the workflow; its smaller revenue base means even modest environmental-order acceleration can support narrative-driven multiple expansion. A is also leveraged through LC-MS and consumables, while TMO/DHR benefit more through installed-base monetization and laboratory automation than headline instrument volume.

The more investable second-order effect is laboratory-network consolidation. Scale operators can spread method validation, contamination-control protocols, accreditation, and legal-compliance overhead across high sample volumes, raising barriers for independent labs and improving turnaround-time economics. SGSN is best positioned among listed testing networks to convert compliance demand into cross-selling, but its valuation should be tested against organic environmental-testing growth rather than extrapolated from acquisitions; capacity utilization and pricing, not laboratory count, determine incremental margins.

Near term, this release is not a stand-alone catalyst: it is vendor-sponsored TAM research with no order, pricing, or regulatory-enforcement datapoint. Over 1-3 months, watch U.S. utility procurement, state monitoring budgets, and quarterly environmental instrument orders; a broadening of analyte panels favors HRMS and software, whereas standardized routine panels favor lower-cost triple-quadrupole systems and high-throughput labs. Over 6-18 months, remediation spending may shift economics toward treatment vendors and recurring verification testing, but delayed implementation, underfunded municipalities, or successful legal challenges to limits would defer capex.

Consensus may over-credit instrument vendors for a compliance cycle that is operationally constrained by sample preparation, qualified personnel, and lab capacity. The cleanest expression is therefore selective WAT/A exposure versus a broad life-science-tools basket, not a beta-heavy long TMO or DHR; conversely, a larger-than-expected testing backlog would be more material to SGSN than to the instrument conglomerates.

Key Decisions for Investors

• Watch-list long WAT versus short IHI or equal-dollar long WAT/short TMO for 3-6 months only after management cites environmental/LC order growth or consumables acceleration. Target 10-15% relative upside if the workflow narrative lifts estimates; exit if instrument-bookings commentary remains flat for two quarters.
• Accumulate A on pullbacks for a 6-12 month compliance-workflow cycle, with a 5-7% position risk limit. Require evidence of LC-MS backlog, environmental end-market growth, or consumables attachment at the next earnings print; absent those data, this remains an alert rather than a recommendation.
• Monitor SGSN for a 6-18 month long entry following disclosure of PFAS-related pricing, utilization, or organic environmental-testing growth. Prefer entry after acquisition integration metrics confirm margin stability; avoid chasing M&A headlines because dilution, integration costs, and weak municipal budgets can offset volume growth.
• Do not initiate a directional TMO or DHR trade on this development. PFAS is immaterial to group earnings; reassess only if environmental instrument orders become a disclosed driver of guidance or if broader regulatory enforcement produces a visible capex cycle.